Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Zochling

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Arthritis Care & Research|August 29, 2013
Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activityKathleen Tymms, Jane Zochling, James Scott, et al.
International Journal of Rheumatic Diseases|July 22, 2017
Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian studyKathleen Tymms, Ayano Kelly, Paul Bird, et al.
The Journal of Rheumatology|January 17, 2013
The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritisPaul Bird, Hedley Griffiths, Kathleen Tymms, et al.
International Journal of Rheumatic Diseases|October 30, 2013
A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease controlGeoffrey Littlejohn, Lynden Roberts, Mark Arnold, et al.
The Cochrane Database of Systematic Reviews|April 19, 2015
TNF-alpha inhibitors for ankylosing spondylitisLara J Maxwell, Jane Zochling, Annelies Boonen, et al.
International Journal of Rheumatic Diseases|April 18, 2015
Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e InitiativeScott W Graf, Samuel L Whittle, Mihir D Wechalekar, et al.
Clinical and Experimental Rheumatology|April 7, 2016
Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort StudyClaire Owen, Gene-Siew Ngian, Kathleen Elford, et al.
Clinical and Experimental Rheumatology|October 3, 2018
The role of inflammatory markers in assessment of disease activity in systemic sclerosisLaura Ross, Wendy Stevens, Candice Rabusa, et al.
Clinical and Experimental Rheumatology|May 24, 2016
The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Arthritis Research & Therapy|November 20, 2013
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Arthritis Care & Research|August 29, 2013
Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activityKathleen Tymms, Jane Zochling, James Scott, et al.
International Journal of Rheumatic Diseases|July 22, 2017
Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian studyKathleen Tymms, Ayano Kelly, Paul Bird, et al.
The Journal of Rheumatology|January 17, 2013
The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritisPaul Bird, Hedley Griffiths, Kathleen Tymms, et al.
International Journal of Rheumatic Diseases|October 30, 2013
A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease controlGeoffrey Littlejohn, Lynden Roberts, Mark Arnold, et al.
The Cochrane Database of Systematic Reviews|April 19, 2015
TNF-alpha inhibitors for ankylosing spondylitisLara J Maxwell, Jane Zochling, Annelies Boonen, et al.
International Journal of Rheumatic Diseases|April 18, 2015
Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e InitiativeScott W Graf, Samuel L Whittle, Mihir D Wechalekar, et al.
Clinical and Experimental Rheumatology|April 7, 2016
Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort StudyClaire Owen, Gene-Siew Ngian, Kathleen Elford, et al.
Clinical and Experimental Rheumatology|October 3, 2018
The role of inflammatory markers in assessment of disease activity in systemic sclerosisLaura Ross, Wendy Stevens, Candice Rabusa, et al.
Clinical and Experimental Rheumatology|May 24, 2016
The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Arthritis Research & Therapy|November 20, 2013
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Pageof 6